Decoy Therapeutics reports preclinical data backing once-weekly intranasal dosing for DCOY-CoV program

• Decoy Therapeutics disclosed preclinical pharmacokinetic results supporting once-weekly intranasal dosing for its lead DCOY-CoV program.
• The data were scheduled for presentation later on September 29 at the Boulder Peptide Symposium’s Peptide Showcase.
• Findings indicate a single dose could sustain protective drug exposure across upper airways and lungs for about a week.
• The program targets prevention or treatment of endemic human coronaviruses in high-risk patients, where no non-COVID options are approved.
• DCOY-CoV is expected to enter clinical trials in 2027, setting up a key valuation inflection point tied to first-in-human data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE58803) on September 29, 2026, and is solely responsible for the information contained therein.